Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.66 |
| ▸ | HINT1 | P49773 | 2/20 | 0.59 |
| ▸ | NT5E | P21589 | 3/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15336916 | 0.92 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL15958586 | 0.92 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL8619145 | 0.92 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL27418170 | 0.92 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL12150807 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL12300482 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL29100469 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL12031300 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL1527213 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL1527211 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, POLRMT, DCLRE1B | ADORA3 1448/4885HINT1 1707/4885NT5E 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.